NASDAQ$ADMA
ADMA Biologics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
ADMA Biologics' Q2 2024 financial performance was marked by significant revenue and earnings growth, driven by increased sales of ASCENIV and a favorable product mix, leading to upwardly revised financial guidance for 2024 and 2025.
ADMA Biologics reported a strong second quarter in 2024, with a 78% increase in total revenue to $107.2 million and a net income of $32.1 million, driven by increased sales of ASCENIV and a favorable product mix. The company's adjusted EBITDA reached $44.5 million, and based on this performance, ADMA has increased its financial guidance for 2024 and 2025.
- Total revenue for Q2 2024 reached $107.2 million, a 78% increase year-over-year.
- GAAP net income for Q2 2024 was $32.1 million, a $38.4 million increase year-over-year.
- Adjusted EBITDA for Q2 2024 was $44.5 million, representing a nearly 600% increase year-over-year.
- The company increased its full-year 2024 revenue guidance to over $400 million and net income guidance to over $105 million.
Headline financials
Revenue & EPS history
ADMA Biologics · Revenue · Quarterly
$107M
Revenue by segment
ADMA Biologics · $122M total across 1 segment · Q2 2025
- ADMA BioManufacturing$122M—100.0%
Forward guidance
ADMA Biologics has upwardly revised its financial guidance for FY 2024 and 2025. Total revenue is now expected to be more than $400 million and $445 million, respectively. Net income is projected to exceed $105 million and $155 million, respectively. Adjusted EBITDA is anticipated to surpass $150 million and $200 million, respectively.
Tailwinds
- Total revenue is now expected to be more than $400 million and $445 million for FY 2024 and 2025, respectively.
- Net income is now expected to exceed $105 million and $155 million for FY 2024 and 2025, respectively.
- Adjusted EBITDA is now expected to exceed $150 million and $200 million for FY 2024 and 2025, respectively.
- Commercial-scale production of ADMA’s innovative biologics manufacturing process demonstrated a potential enhancement of yields by approximately 20% from the same starting plasma.
- The ongoing post-marketing pediatric clinical study for ASCENIV may provide label expansion opportunities.
Headwinds
- Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially.
- There can be no assurance that the forward-looking statements included in this press release will prove to be accurate.
- The company's yield enhancement initiative may not be successful.
- The R&D program targeting S. pneumoniae may not be successful.
- The ASCENIV label expansion may not be successful.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
+2.5%
Avg return
Earnings day
+3.7%
Avg return
5 days after
+6.4%
Avg return
30 days after
50%
20 / 40 earnings
Positive
+39.4%
Q2 2024
Best reaction
-17.4%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -1.7% | -23.1% | -22.2% | |
| Q4 2025 | -3.6% | +4.5% | -41.0% | |
| Q3 2025 | -8.4% | +4.3% | +29.1% | |
| Q1 2025 | -10.2% | -15.8% | -12.7% | |
| Q4 2024 | +7.5% | +7.5% | +22.9% | |
| Q3 2024 | +15.0% | +10.7% | +0.8% | |
| Q2 2024 | +39.4% | +50.8% | +42.0% | |
| Q1 2024 | +28.4% | +33.5% | +52.6% | |
| Q4 2023 | -2.9% | +3.6% | +19.6% | |
| Q3 2023 | +3.8% | +1.4% | +0.5% | |
| Q2 2023 | +4.1% | +11.4% | -7.2% | |
| Q1 2023 | +14.1% | +20.7% | +10.1% | |
| Q4 2022 | +10.3% | +6.6% | +18.9% | |
| Q3 2022 | +20.7% | +26.8% | +36.0% | |
| Q2 2022 | +9.9% | +18.7% | +40.4% | |
| Q1 2022 | +4.3% | +16.1% | +20.5% | |
| Q4 2021 | +11.6% | +25.3% | +36.3% | |
| Q3 2021 | +12.0% | +9.2% | -6.3% | |
| Q2 2021 | -1.9% | -6.5% | -22.7% | |
| Q1 2021 | -6.4% | +0.0% | +5.2% | |
| Q4 2020 | -8.6% | -13.6% | -4.0% | |
| Q3 2020 | -10.7% | -15.0% | -6.5% | |
| Q2 2020 | -15.1% | -9.8% | -34.1% | |
| Q1 2020 | -17.4% | -15.8% | -6.2% | |
| Q4 2019 | -6.5% | -13.4% | +18.2% | |
| Q3 2019 | -12.1% | -14.6% | -16.0% | |
| Q2 2019 | +3.9% | +15.2% | +40.3% | |
| Q1 2019 | +7.7% | -1.0% | -21.3% | |
| Q4 2018 | +0.0% | +7.9% | +25.4% | |
| Q3 2018 | -8.7% | -11.3% | -17.7% | |
| Q2 2018 | -4.1% | -6.5% | +0.3% | |
| Q1 2018 | +5.8% | +9.0% | -4.0% | |
| Q4 2017 | -0.3% | +10.5% | +26.8% | |
| Q3 2017 | -6.8% | -2.0% | +35.1% | |
| Q2 2017 | +1.7% | +4.8% | +17.9% | |
| Q1 2017 | +0.7% | -8.3% | -18.4% | |
| Q4 2016 | -0.6% | -5.0% | +0.8% | |
| Q3 2016 | +17.9% | +17.0% | -3.3% | |
| Q2 2016 | +6.4% | -9.2% | -7.2% | |
| Q4 2014 | +0.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro